Mattel launches Barbie with Type 1 diabetes and a glucose monitor
Mattel announced the newest member of its Barbie Fashionistas line on Tuesday, saying that it not only lets children see themselves in the doll, but also encourages play "that extends beyond a child's own lived experience." The doll has a continuous glucose monitor attached to her arm and an insulin pump attached to her waist.
Krista Berger, senior vice president for Barbie and global head of dolls, said in a news release that the doll "marks an important step in our commitment to inclusivity."
"Barbie helps shape children's early perceptions of the world, and by reflecting medical conditions like T1D, we ensure more kids can see themselves in the stories they imagine and the dolls they love," Berger said.
The Mayo Clinic defines Type 1 diabetes as a chronic condition that results when a person's pancreas creates little to no insulin, the hormone that helps glucose get into cells, where it's broken down. A glucose monitor allows someone with the condition to keep track of their sugar levels and inject insulin to help their body process glucose.
An insulin pump is a wearable device that allows for an easy supply of insulin into the body.
More than 18,000 young people under the age of 20 were diagnosed with Type 1 diabetes in the U.S. last year, according to the Centers for Disease Control and Prevention. The agency reported that there's been about a 2% increase per year in diagnosed cases between 2002 and 2018.
Barbie partnered with the nonprofit organization Breakthrough T1D in the development of its new doll and to ensure an accurate reflection of the devices, the release said. Breakthrough T1D CEO Aaron J. Kowalski said he was "thrilled" when the company proposed a collaboration.
"I have lived with T1D since I was 13, and my brother since he was 3, so this partnership is deeply personal – it means the world to be part of bringing greater visibility to a condition that affects so many families," Kowalski said.
A link to buy the doll on Mattel's website appears to already have reviews from parents who were sent the doll, as the website notes the reviews are "incentivized."
One parent wrote that they gave the doll to their 7-year-old daughter and it opened up a conversation about diabetes. Another parent called it a "great addition" to the Barbie brand.
"We have a close family friend who is T1D, so this was an excellent opportunity to explain what each item was and what it does to help keep people safe and healthy," the review said.
This article was originally published on NBCNews.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
2 Healthcare Stocks That Are Losing to the S&P 500 This Year
Key Points Novo Nordisk and Regeneron have encountered challenges recently. Both companies are significantly trailing the market this year. These healthcare leaders still could perform well in the long run. 10 stocks we like better than Novo Nordisk › Even with all the volatility and the flirting with bear-market territory, the S&P 500 index is well in the green this year, up about 8% since early January. Some stocks haven't been so lucky, though. Novo Nordisk (NYSE: NVO) and Regeneron Pharmaceuticals (NASDAQ: REGN), two leading drugmakers, have underperformed for most of the year, significantly lagging the broader market. These healthcare giants are facing some headwinds, but does that mean investors should steer clear of them? Let's find out. 1. Novo Nordisk Novo Nordisk has been facing several challenges that predate this year. It encountered a clinical setback for what Wall Street thought was a promising weight management candidate. Furthermore, the company's financial results, although strong when compared to its similarly sized peers, were not seen as sufficient because it's held to a higher standard. These challenges have led to a terrible performance this year. Novo Nordisk's shares are down by 18% year to date, significantly lagging the S&P 500. However, the stock might be a steal right now. The company has made several moves that should allow it to recover. Novo Nordisk's pipeline, especially in diabetes and weight management, remains one of the strongest in the industry. It recently initiated a phase 3 study for amycretin -- its next-generation GLP-1 medicine -- in both subcutaneous and oral formulations. It requested regulatory approval in the U.S. for an oral version of semaglutide, its well-known medicine marketed as Wegovy for weight loss and as Ozempic for diabetes management. Novo Nordisk has also penned several licensing deals that have expanded its pipeline in weight management. The company should launch at least one new medicine in its core therapeutic area within the next few years. Financial results should remain strong as Ozempic and Wegovy continue driving solid revenue growth. Considering the stock's sell-off over the past years, shares now look more than reasonably valued relative to Novo Nordisk's growth potential. Their forward price-to-earnings ratio of 16.9 is in line with the healthcare industry's average of 16.5 as of this writing. However, Novo Nordisk typically grows its revenue and earnings faster than its peers. That makes its stock attractive at current levels, based on its growth potential. 2. Regeneron Pharmaceuticals Regeneron is facing biosimilar competition for Eylea, a medicine for wet age-related macular degeneration that was once one of its biggest growth drivers. Sales of the medicine have dropped, dragging total revenue down with them. That's the most important reason why Regeneron's shares are down by 19% since the year started. However, the stock is still attractive. The biotech might go through a period of its top line declining, but it can still recover. Here are three reasons why. First, the company's newer, higher-dose (HD) formulation of Eylea is taking market share away from its previous version. HD Eylea is performing well and will grow even faster once it earns some label expansions. Second, Regeneron has a deep pipeline that's expected to yield new brand approvals. Earlier this month, it earned the green light for Lynozyfic, a cancer medicine, in the U.S. One of its more promising candidates is a gene therapy for one type of genetic deafness, which is showing incredible potential in clinical trials. Regeneron should move beyond Eylea thanks to newer approvals. Third, the company's most important product, Dupixent, an eczema treatment, is performing exceptionally well. The medicine has earned important label expansions in recent years, including in treating chronic obstructive pulmonary disease (COPD) and a rare skin condition called bullous pemphigoid. Dupixent will maintain its upward growth trajectory for a while. Here's one more reason to invest in Regeneron: The company is committed to returning capital to shareholders. It recently initiated a dividend and has a robust share-buyback program in place. The stock might be moving in the wrong direction right now, but those willing to hold onto it for five years or more could see superior returns over the long run. Should you invest $1,000 in Novo Nordisk right now? Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,628!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,063,471!* Now, it's worth noting Stock Advisor's total average return is 1,041% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 21, 2025 Prosper Junior Bakiny has positions in Novo Nordisk. The Motley Fool has positions in and recommends Regeneron Pharmaceuticals. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. 2 Healthcare Stocks That Are Losing to the S&P 500 This Year was originally published by The Motley Fool Connectez-vous pour accéder à votre portefeuille
Wall Street Journal
33 minutes ago
- Wall Street Journal
Vinay Prasad Is a Bernie Sanders Acolyte in MAHA Drag
Meet Vinay Prasad, a young disciple of Bernie Sanders who ranks as one of the most powerful officials in the federal government. He determines whether patients get access to many life-saving medicines. Or not. Think of him as a one-man death panel. Dr. Prasad was named by Marty Makary, the Food and Drug Administration commissioner, as head of the agency's biologics division in May, and last month as its chief medical and scientific officer. More on why he was tapped to these posts later. But it isn't an exaggeration to say that Dr. Prasad wields more power than Anthony Fauci ever did at the National Institutes of Health.
CBS News
an hour ago
- CBS News
Maryland Institute College of Art teams up with senior living center for art display
A unique partnership between the Maryland Institute College of Art (MICA) and a senior living center is on display in Baltimore. MICA's community arts program agreed to lead art classes for the residents of the North Oaks Senior Living Community, with their artwork out for all visitors to admire at its Fred Lazarus Center. North Oaks is a multi-level retirement community that offers independent living, assisted living, skilled nursing, and rehabilitation. "When you have an opportunity to express yourself, you never know what's going to come out," said Susan Sidle, a North Oaks Senior Living Community resident. The exhibit will be on display through Sunday, August 3. Lorena Garcia, a MICA graduate student, taught the classes during her 2025 spring semester to more than 30 residents at North Oak. "Our goal was really not to just work one specific medium, such as just painting, but to explore collages, to explore clay, to explore jewelry making," Garcia said. According to research from the National Library of Medicine, creative activities like arts and crafts can promote healthy aging, even prolong someone's life. Research also shows that creating art can help improve small motor skills and boost self-confidence. "In the community arts program, we work with a variety of intergenerational populations throughout Baltimore city, providing art space and educational workshops for them and with them as well," said Unique Robinson, the director of community arts at MICA. "To make something that you're proud of, to discover a different aspect of yourself, I think is something is something at any age you can do," Garcia added. North Oaks Senior Living Community residents Jules and Susan Sidle aren't your typical artists or couple. For the Sidles and their friends, Gloria Greenspun and Nadine Goldman, art is timeless. As a matter of fact, they told WJZ most of them have never painted or had their work on display in an art exhibit before. "I had the best time and smiled and laughed and had a great time and learned something as well," Greenspun said. "I felt better about myself." The four residents who have known each other for decades decided the art class would be an enjoyable activity they could do together. "Everybody has a skill, you just have to use it," said Jules Sidle.
